Authors

Latest:

Recognizing the Role of Bias in Patient Decision Making

Doctors are taught to think through medical decisions by listing a series of options, weighing the risks and benefits of each, and ultimately concluding on the superior option. This comparative maximization approach is drilled into us as medical students and residents.

Ravi Salgia, MD, PhD

Latest:

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

Ravi Vij, MD

Latest:

Dr. Vij on the Integration of Selinexor in Relapsed/Refractory Multiple Myeloma

Ravi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.

Ravi Vij, MD, MBA

Latest:

Dr. Vij on the Potential of CELMoDs in Relapsed/Refractory Multiple Myeloma

Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.

Ravindra Uppaluri, MD, PhD

Latest:

Study Adds Pembrolizumab to Paradigm for Certain Head and Neck Cancers

A group of researchers at Washington University in St. Louis recently opened a clinical trial to evaluate pembrolizumab as treatment intensification therapy for patients with high-risk locoregionally advanced, previously untreated, HPV-negative head and neck squamous cell carcinomas.

Raymond U. Osarogiagbon, MD, FACP

Latest:

Dr. Osarogiagbon on the Effects of the COVID-19 Pandemic on Lung Cancer Screening

Raymond U. Osarogiagbon, MD, FACP, discusses the long-term effects of the COVID-19 pandemic on lung cancer screenings.

Rebecca Arend, MD

Latest:

Dr. Arend Discusses Targets in Endometrial Cancer

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.

Rebecca C. Arend, MD

Latest:

FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

A brief review of the FDA approval and implications of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

Rebecca Clark-Snow, RN, BSN, OCN, University of Kansas Cancer Center

Rebecca Dent, MD

Latest:

Dr. Dent on Final LOTUS Findings in TNBC

Rebecca Dent, MD, discusses the findings from the phase 2 LOTUS trial that treated patients with inoperable locally advanced/metastatic triple-negative breast cancer with first-line ipatasertib plus paclitaxel.

Rebecca Feldman, PhD

Latest:

Rebecca Feldman on Oncogenic Role of Caveolin-1 in Breast Cancer

Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1 as potentially having an oncogenic role in breast cancer.

Rebecca Kristeleit, BSc, PhD

Latest:

Dr Kristeleit on the Implications of Long-Term Data With Rucaparib in Advanced Ovarian Cancer

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Rebecca Kronk, PhD, CRNP, MSN, Duquesne

Rebecca L. Aft, MD, PhD

Latest:

Dr. Aft on Bisphosphonates for Breast Cancer

Rebecca L. Aft, MD, PhD, professor of surgery at the Washington University School of Medicine in St. Louis and a physician at Siteman Cancer Center, discusses the use of bisphosphonates for patients with breast cancer.

Rebecca L. Olin, MD, MSCE

Latest:

Dr. Olin on the Rationale to Evaluate Menin Inhibitors in AML

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.

Rebecca M. Minter, MD

Latest:

Prevention Program Targets Pancreatic Cancer Before It Gains a Foothold

Pancreatic cancer is currently the fourth-leading cause of cancer death in the United States, with a 5-year survival rate of approximately 8%.

Rebecca S. Sippel, MD

Latest:

Dr. Sippel Explains Thyroid Cancer Risk Factors

Rebecca S. Sippel, MD, from University of Wisconsin, explains the need for added screening for those at high-risk of developing thyroid cancer.

Reed D. Gelzer, MD, MPH, CHCC

Latest:

The EAR Party's End

Electronic Health Record (EHR) systems hold great promise. However, like many new technologies, the difficulty of achieving EHRs' promise has been vastly underestimated, as have the risks. The current national initiatives pushing for widespread EHR implementation may be leading us into an unmapped minefield.

Reed Friend, MD

Latest:

Dr. Friend on the Importance of Work-up for Patients With Multiple Myeloma

Reed Friend, MD, a medical oncologist in hematology and medical oncology, of Levine Cancer Institute and Carolinas HealthCare System, discusses the importance of appropriate work-ups for patients with multiple myeloma.

Reem Karmali, MD

Latest:

Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCL

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).